Samsung Biologics said Monday that it has been awarded the Platinum medal, the highest rating awarded to only the top 1 percent of companies worldwide, in the ESG assessment by global sustainability research organization EcoVadis.

After achieving a Gold rating in 2022, Samsung Biologics moved up a notch in the 2023 assessment, reaching the top tier of Platinum. 

Founded in France in 2007, EcoVadis annually assesses more than 100,000 companies in 175 countries worldwide in four areas: environment, labor and human rights, ethics, and sustainable procurement, awarding platinum, gold, silver, and bronze ratings.

EcoVadis’ ESG assessments are globally recognized as a reliable supply chain assessment metric. Global pharmaceutical companies such as GSK and AstraZeneca also consider it as a key determinant in evaluating their suppliers' sustainability performance.

Samsung Biologics was recognized for strategically advancing its ESG policies, and expanding its participation in global initiatives such as the U.K. Sustainable Markets Initiative (SMI) and the United Nations Global Compact (UNGC).

In labor and human rights, the company was also recognized for its systematic operational excellence in policy and reporting, implementing a labor and human rights policy with diversity and equity.

In July last year,  Samsung Biologics jointly issued an open letter to six global pharmaceutical companies, including GSK, AstraZeneca, and Merck, calling on its suppliers to actively participate in the movement against climate change.

"Our efforts to address climate change and systematic supply chain management have resulted in international recognition of our ESG competitiveness," said John Rim, CEO of Samsung Biologics. "We will continue to fulfill our social responsibility as a global top-tier CDMO company."